TEMPE, Ariz., Aug. 7, 2008 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, has shown a statistically significant benefit in a recently completed pre-clinical study designed to assess cardioprotective effects in a model of acute myocardial infarction (heart attack).
